Noven Pharmaceuticals Inc. (Nasdaq: NOVN) shares are up more than 20 percent to $16.50 in early premarket volume after it agreed to be bought by Hisamitsu Pharmaceutical for $428 million in cash or $16.50 per share. The deal was unanimously approved by the boards of both companies. Also, Noven announced what it called positive top-line results from its Phase 2 clinical think evaluating Mesafem for the treatment of vasomotor symptoms associated with menopause. — Mike Tarsala
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment